Physician profile
Michael P Carroll
NPI 1699748707
$33,150.04
in general payments reported to CMS, 2019-2025
11 companies · $20.04 in 2025
The $20.04 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $1,500 · 2021: $241 · 2022: $3,420 · 2023: $19.73 · 2025: $20.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $12,108.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $9,142.71 | 2019 | |
| Celgene Corporation | $8,178.10 | 2019-2020 | |
| Cti Biopharma Corp. | $1,725.00 | 2022 | |
| Abbvie INC. | $1,650.00 | 2022 | |
| Astellas Pharma US INC | $198.00 | 2021 | |
| Pfizer INC. | $96.45 | 2019-2022 | |
| Novo Nordisk INC | $20.04 | 2025 | |
| Axsome Therapeutics, INC. | $19.73 | 2023 | Auvelity |
| Epizyme, INC. | $11.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.